A Quote by Amy Klobuchar

I am deeply troubled by Mylan's misclassification of the EpiPen as a generic drug. — © Amy Klobuchar
I am deeply troubled by Mylan's misclassification of the EpiPen as a generic drug.
Over the years, EpiPen's manufacturer, Mylan, made meaningful modifications to its auto-injector pen. The company maintains some important intellectual property around these revisions. Mylan rightly argues that these features differentiate its device.
Where there's a lack of competition - as we saw with Mylan Pharmaceutical's virtual monopoly on EpiPen - price increases often follow.
EpiPen is not unique. It falls into a category of old drugs, many of which should have long been subject to generic competition.
The higher cost of getting a generic drug approved by regulators means that many old medicines don't face competitors. It's only after substantial price hikes that these drugs offer enough revenue to offset the rising generic entry costs, and start to entice competition.
I had a troubled childhood, a troubled adulthood but now I am totally healed. I am lucky that there are people around me to support.
I wouldn't say I have felt troubled here at United. I am not troubled. I am lucky. I have loved my time here.
The value that the generic drug industry brings to the U.S. healthcare system is indisputable.
'Chels-emojis' are in the works. I use emojis heavily in life, and I think a lot of people do. There are a number that are frustratingly absent - you know how there's kind of a generic white man and a generic white woman? I just want to put a generic black man and a generic black woman.
The regulatory approach of the Food and Drug Administration and the Patent and Trademark Office has driven up the costs of generic drugs.
The key to the generic-drug economic model is to keep entry prices low enough to attract multiple competitors.
A horse walks into a bar, and the barman says "Why the long face?". The horse replies: "I'm deeply troubled by the anthropomorphic aspects of my existence and the extent to which I am now protected by law."
We should look for ways to expedite generic drug approvals, particularly for products that have a long history of being safe and effective.
It is not enough to show that drug A is better than drug B on the average. One is invited to ask, 'For which people ("& why") is drug A better than drug B, and vice versa? If drug A cures 40% and drug B cures 60%, perhaps the right choice of drug for each person would result in 100% cures.'
Increasing patient access to more affordable, FDA-approved generic and biosimilar medicines is a proven and tested solution to lowering prescription drug costs.
Cipla has already developed a generic version, oseltamivir, which would be much cheaper than Tamiflu, the only available drug effective in treating avian flu.
Everyone is talking about sustainability and resilience, yet all that knowledge is thrown in the bin. [Lagos is] a unique case, but also a test case. It's unbelievably unique, but also it's now considered with a number of really generic opinions, generic solution, generic expectations.
This site uses cookies to ensure you get the best experience. More info...
Got it!